



## LeMaitre Vascular Announces Details for Its December 3rd Investor and Analyst Day

November 30, 2015

BURLINGTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices and implants, announced today that it will webcast its investor and analyst day to be held on December 3, 2015 at Ruth's Chris Steakhouse in New York City.

This event is open to all investors and analysts. It will feature presentations by senior management who will discuss the Company's positioning, corporate strategy and growth opportunities followed by question and answer sessions. During the event, the Company plans to reiterate its financial outlook for the fourth quarter and full year 2015 that it previously announced on October 27, 2015.

To RSVP for in-person attendance, please email Kimberly Cieslak at [kcieslak@lemaitre.com](mailto:kcieslak@lemaitre.com).

A webcast will be available live on the Investor Relations page of the Company's website at [www.lemaitre.com/investor](http://www.lemaitre.com/investor). A recorded replay of the webcast will be available on the same Investor Relations page shortly after the conclusion of the event.

### About LeMaitre Vascular

LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at <http://www.lemaitre.com>.

LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.

### Forward-Looking Statements

Statements made in this release may be forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such "forward-looking statements" regarding the Company's business that are not historical facts may involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, the risk that the Company may not realize the anticipated benefits of its strategic activities; the risk that assumptions about the market for the Company's products and the productivity of the Company's direct sales force and distributors may not be correct; risks related to the integration of acquisition targets; risks related to product demand and market acceptance of the Company's products and pricing; the risk that the XenoSure product is not as accretive and does not achieve the gross margins currently anticipated by the Company; the risk that the Company is not successful in transitioning to a direct-selling model in new territories; adverse or fluctuating conditions in the general domestic and global economic markets and other risks and uncertainties included under the heading "Risk Factors" in its most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at <http://www.lemaitre.com> and on the SEC's website at <http://www.sec.gov>. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

LeMaitre Vascular, Inc.  
Kimberly Cieslak  
+1-781-425-1653  
[kcieslak@lemaitre.com](mailto:kcieslak@lemaitre.com)  
<http://www.lemaitre.com>

 Primary Logo

LeMaitre Vascular, Inc.